SARS-CoV-2, the causative agent behind the ongoing pandemic exhibits an enhanced potential for
infection when compared to its related family members- the SARS-CoV and MERS-CoV; which have
caused similar disease outbreaks in the past. The severity of the global health burden, increasing
mortality rate and the emergent economic crisis urgently demands the development of next- generation
vaccines. Amongst such emergent next generation vaccines are the multi-epitope subunit vaccines, which
hold promise in combating deadly pathogens. In this study we have exploited immunoinformatics
applications to delineate a vaccine candidate possessing multiple B and T cells epitopes utilizing the
SARS-CoV-2 non structural... More
SARS-CoV-2, the causative agent behind the ongoing pandemic exhibits an enhanced potential for
infection when compared to its related family members- the SARS-CoV and MERS-CoV; which have
caused similar disease outbreaks in the past. The severity of the global health burden, increasing
mortality rate and the emergent economic crisis urgently demands the development of next- generation
vaccines. Amongst such emergent next generation vaccines are the multi-epitope subunit vaccines, which
hold promise in combating deadly pathogens. In this study we have exploited immunoinformatics
applications to delineate a vaccine candidate possessing multiple B and T cells epitopes utilizing the
SARS-CoV-2 non structural and structural proteins. The antigenicity potential, safety, structural stability
and the production feasibility of the designed construct was evaluated computationally. Furthermore, due
to the known crucial interactions of human TLR-3 immune receptor with SARS-CoV, the vaccine construct
was examined for its binding eciency
using molecular docking and molecular dynamics simulation
studies, which resulted in strong and stable interactions. Finally, the immune simulation studies
suggested an effective immune response on vaccine administration. Overall, the immunoinformatics
analysis advocates that the purposed vaccine candidate is safe and immunogenic and therefore can be
pushed as a lead for in vitro and in vivo investigations